DURECT Corp (DRRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
56
About the Report
About the Report
Summary
DURECT Corp (Durect) is a specialty pharmaceutical company. It carries out the development of pharmaceutical systems based on its proprietary drug delivery technology platforms to treat chronic debilitating diseases. It also undertakes the development of biotechnology products. The company's major products include Alzet, an osmotic pump; and Lactel, a biodegradable polymer. The company's product pipeline comprises DUR-928 indicated for treatment of acute organ injuries and metabolic/lipid disorders; Remoxy, indicated for chronic pain; Posimir, indicated for post-operative pain; Eladur, indicated for post herpetic neuralgia; Oradur, indicated for chronic pain and attention deficit hyperactivity disorder; and Relday, indicated for Schizophrenia and bipolar disorder. Durect's major drug delivery technology platforms include Saber, Cloud, Oradur and Transdur. The company operates in the US, Europe, Japan and other countries. Durect is headquartered in California, the US.
DURECT Corp (DRRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
DURECT Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
DURECT Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Durect Enters into Licensing Agreement with Santen Pharma 12
Licensing Agreements 13
Sandoz Amends Licensing Agreement with DURECT 13
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14
Otonomy Enters into Licensing Agreement with Durect 16
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17
Equity Offering 18
Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22
Durect Completes Public Offering Of Shares For USD 11.5 Million 23
Durect Completes Public Offering Of Shares For USD 13 Million 24
Asset Transactions 25
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp-Key Competitors 26
DURECT Corp-Key Employees 27
DURECT Corp-Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 01, 2018: DURECT announces second quarter 2018 financial results and provides corporate update 29
May 02, 2018: DURECT Reports First Quarter 2018 Financial Results 31
Mar 01, 2018: DURECT Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs 33
Nov 01, 2017: DURECT Announces Third Quarter 2017 Financial Results and Provides Corporate Update 35
Aug 08, 2017: DURECT Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 10, 2017: DURECT Announces First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 14, 2017: DURECT Announces Fourth Quarter and Full Year 2016 Financial Results and Update of Programs 41
Corporate Communications 43
Oct 01, 2018: DURECT names Michael H. Arenberg as Chief Financial Officer 43
Oct 01, 2018: DURECT names Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer 44
Sep 20, 2017: DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development 45
Product News 46
09/18/2018: DURECT Announces Methydur sustained release capsules receive marketing authorization for ADHD in Taiwan 46
02/20/2018: DURECT to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) 47
Clinical Trials 48
Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis 48
Feb 26, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis 49
Aug 08, 2017: ORADUR-Methylphenidate ER Capsule Achieves Primary Endpoint in Phase 3 Study in ADHD in Taiwan 50
Jun 22, 2017: DURECT Completes Enrollment in PERSIST, Phase 3 trial for POSIMIR 51
Apr 24, 2017: DURECT Announces Presentation of Data from a Phase 1b Study of DUR-928 in Nonalcoholic Steatohepatitis at The International Liver Congress 2017 52
Apr 17, 2017: DURECT to Present Clinical Data at the International Liver Congress 2017 53
Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Figure
List of Figures
DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DURECT Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
DURECT Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
DURECT Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
DURECT Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
DURECT Corp, Deals By Therapy Area, 2012 to YTD 2018 9
DURECT Corp, Medical Devices Deals, 2012 to YTD 2018 10
DURECT Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Durect Enters into Licensing Agreement with Santen Pharma 12
Sandoz Amends Licensing Agreement with DURECT 13
Impax Labs Enters Into Licensing Agreement With Durect For Eladur 14
Otonomy Enters into Licensing Agreement with Durect 16
Durect Enters Into Licensing Agreement with Virginia Commonwealth University Intellectual Property Foundation 17
Durect Plans to Raise up to USD175 Million in Public Offering of Securities 18
Durect Raises USD17.3 Million in Public Offering of Shares 19
Durect Files Registration Statement For Public Offering Of Securities For USD 100.9 Million 21
Durect Files Registration Statement For Public Offering Of Common Stock For Up To USD 25 Million 22
Durect Completes Public Offering Of Shares For USD 11.5 Million 23
Durect Completes Public Offering Of Shares For USD 13 Million 24
Indivior Acquires Certain US Patent Rights from Durect 25
DURECT Corp, Key Competitors 26
DURECT Corp, Key Employees 27
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.